Siparex, a private equity group, buys minority stake in Pharmactive
The private equity group Siparex has purchased a minority stake in Pharmactive, which will allow the firm to accelerate its development plans through external growth and expand its portfolio of natural ingredients and international commercial presence.
Photo © iStockphoto.com/skynesher
Private Equity group Siparex (Paris, France) has taken a minority stake in Pharmactive (Madrid, Spain), a science-based botanical ingredient leader with premium products affron saffron extract and ABG10+, a black garlic extract. The company forecasts sales of around €12 million by the end of fiscal 2021.
“It’s exciting to collaborate with such a well-established PE,” said Jean-Marie Raymond, CEO and founder of Pharmactive, in a press release. “This new investment round marks a significant milestone for our company. We experienced expansive growth in 2020, despite the pandemic, and strong sales growth is forecast to continue in 2021. Consumers are seeking science-supported, natural mental-wellness solutions, and Pharmactive can fulfill this demand and other emerging trends with branded ingredients backed by science.”
The transaction with Siparex Midcap will allow Pharmactive to accelerate its development plans through external growth and expand its portfolio of natural ingredients and international commercial presence.
“Positioned in a booming market, Pharmactive is an innovative company led by an experienced and enthusiastic founding manager,” said Pierre Bordeaux Montrieux, managing director of Siparex Midcap, in a press release. “Pharmactive stands out in particular with its unique validation positioning and systematic scientific analysis of premium products,” adds Stéphane Agaësse, Senior Investment Manager within Siparex Midcap. “We are proud to support them in this new phase of development.”
Kaneka Nutrients to unveil new consumer research on menopausal women at Vitafoods Europe 2024
April 26th 2024The company will reveal the results of the research that is based on live feedback from 200 menopausal women who took 200 mg per day of Kaneka Ubiquinol over two-months, monitored the effects, and recorded their observations.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
